The Protein Corona on Nanoparticles for Tumor Targeting in Prostate Cancer—A Review of the Literature and Experimental Trial Protocol DOI Creative Commons

Giulio Bevilacqua,

Roberta Corvino,

Anna Laura Capriotti

и другие.

Biology, Год журнала: 2024, Номер 13(12), С. 1024 - 1024

Опубликована: Дек. 7, 2024

The National Cancer Institute (NCI) recognizes the potential of technologies based on use nanoparticles (NPs) in revolutionizing clinical approaches to diagnosis and prognosis cancer. Recent research suggests that once NPs come into contact with biological fluid cancer patients, they are covered by proteins, forming a “protein corona” composed hundreds plasma proteins. concept personalized, disease-specific protein corona, demonstrating substantial differences NP corona profiles between patients without cancer, has been introduced. We developed design an experimental prospective single-center study allocated 1:1:1 ratio one three arms: untreated benign prostatic hyperplasia (BPH), non-metastatic prostate (PCa), metastatic starting systemic therapies new androgen-targeted agents or taxanes. protocol aims develop implement sensitive nanotools two distinct objectives: First, capable selectively binding detecting biomarkers order build predictive diagnostic model effectively discriminate patient sera affected BPH PCa. Secondly, within population PCa, case initial advanced diagnosis, objective is find predicting response treatments improve precision efficiency monitoring treatment outcomes. For metabolite experiments, we cross-reactive sensor array platform detection capacity made liposomal formulations different surface charges. proteomic-NP studies, proteins were identified quantified using nano-high-performance LC (nanoHPLC) coupled MS/MS (nanoHPLC−MS/MS). Metabolites instead analyzed untargeted metabolomic approach. Compared previous review articles, novelty this represented analysis possible applications focused PCa presentation phase

Язык: Английский

Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces DOI Creative Commons
Hao Wang, Feirong Gong, Jiajie Liu

и другие.

Bioengineering, Год журнала: 2024, Номер 11(11), С. 1078 - 1078

Опубликована: Окт. 28, 2024

Docetaxel has exhibited excellent therapeutic effects in cancer treatment; however, its hydrophobicity, short blood circulation time, and high toxicity restrict clinical application. The use of mPEG-PLA micelles to deliver docetaxel into the body been verified as an effective approach enhance efficacy. However, are easily disassembled bloodstream, which can lead premature drug release. To broaden application scenarios mPEG PLA micelles, we utilized π–π stacking effect intermolecular force design a novel mPEG-PLA-Lys(Fmoc) micelle stability permeability drug-loaded micelles. result showed that for injection did not alter tissue selectivity docetaxel. Intravenous nude mice better antitumor efficacy than tumor recurrence rate is 0%, significantly lower (100%). designed by this research institute anticipated improve

Язык: Английский

Процитировано

1
The Protein Corona on Nanoparticles for Tumor Targeting in Prostate Cancer—A Review of the Literature and Experimental Trial Protocol DOI Creative Commons

Giulio Bevilacqua,

Roberta Corvino,

Anna Laura Capriotti

и другие.

Biology, Год журнала: 2024, Номер 13(12), С. 1024 - 1024

Опубликована: Дек. 7, 2024

The National Cancer Institute (NCI) recognizes the potential of technologies based on use nanoparticles (NPs) in revolutionizing clinical approaches to diagnosis and prognosis cancer. Recent research suggests that once NPs come into contact with biological fluid cancer patients, they are covered by proteins, forming a “protein corona” composed hundreds plasma proteins. concept personalized, disease-specific protein corona, demonstrating substantial differences NP corona profiles between patients without cancer, has been introduced. We developed design an experimental prospective single-center study allocated 1:1:1 ratio one three arms: untreated benign prostatic hyperplasia (BPH), non-metastatic prostate (PCa), metastatic starting systemic therapies new androgen-targeted agents or taxanes. protocol aims develop implement sensitive nanotools two distinct objectives: First, capable selectively binding detecting biomarkers order build predictive diagnostic model effectively discriminate patient sera affected BPH PCa. Secondly, within population PCa, case initial advanced diagnosis, objective is find predicting response treatments improve precision efficiency monitoring treatment outcomes. For metabolite experiments, we cross-reactive sensor array platform detection capacity made liposomal formulations different surface charges. proteomic-NP studies, proteins were identified quantified using nano-high-performance LC (nanoHPLC) coupled MS/MS (nanoHPLC−MS/MS). Metabolites instead analyzed untargeted metabolomic approach. Compared previous review articles, novelty this represented analysis possible applications focused PCa presentation phase

Язык: Английский

Процитировано

0